Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin

John J. Kavanagh, Katherine Y. Yeung, Niramol Savaraj, Irwin H. Krakoff

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Thirteen patients were treated with both the oral and intravenous preparations of 4-demethoxydaunorubicin (DMDR). The drug was well tolerated in both forms. Neutropenia was the dose-limiting side-effect. Approximately 30% of the compound was absorbed when given orally. The maximum tolerated dose was 12.5 mg/m2 intravenously or 50 mg/m2 (10 mg/m2 q d × 5) orally, given every 21-28 days.

Original languageEnglish (US)
Pages (from-to)1187-1189
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number10
DOIs
StatePublished - Oct 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin'. Together they form a unique fingerprint.

  • Cite this